GoodRx Holdings, Inc.GDRXNASDAQ
Loading
R&D Expense Growth Recovery in ProgressRecovering
Percentile Rank33
Studio
Year-over-Year Change

Year-over-year research & development expense growth

Percentile
P33
Within normal range
vs 5Y Ago
0x
Contraction
Streak
1 yr
Consecutive growthRecovering
PeriodValue
2025-2.20%
2024-8.90%
2023-5.10%
202213.73%
2021103.60%
2020110.98%
2019-33.25%
2018281.65%
2017100.30%
20160.00%